In a nationwide study of 3,818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 in COVID-19 development and progression.
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths
Dauriz M;
2020-01-01
Abstract
In a nationwide study of 3,818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 in COVID-19 development and progression.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0168822720306975.pdf
Open Access dal 02/01/2020
Tipologia:
Documento in Pre-print
Licenza:
Accesso ristretto
Dimensione
508.41 kB
Formato
Adobe PDF
|
508.41 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
